Modulation of the tumor microenvironment is becoming an increasingly popular research
topic in the field of immunotherapy, and studies regarding immune checkpoint blockades …

Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not
the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests …

Tumor immunotherapy has achieved remarkable efficacy, with immune‐checkpoint
inhibitors as especially promising candidates for cancer therapy. However, some issues …

Cancer immunotherapy, including immune checkpoint blockade and CAR-T cell therapy,
has introduced revolutionary approaches to treating patients with cancer. The success and …

Simple Summary Immune checkpoint inhibitors (ICIs) constitute a paradigm shift in cancer
therapy, and it has greatly expanded our knowledge of anticancer immunity and has …

The efficacy of cancer immunotherapy largely depends on the tumor microenvironment,
especially the tumor immune microenvironment. Emerging studies have claimed that …

Cancer immunotherapy appears to be a promising treatment option; however, only a subset
of patients with cancer responds favorably to treatment. Locoregional therapy initiates a …

Harnessing the broad immunostimulatory capabilities of chemotherapy in combination with
immune checkpoint inhibitors has improved immunotherapy outcomes in patients with …

For many decades, cancer treatment has been strongly directed toward the development of
cytotoxic and cytostatic drugs, quite often leading to disappointing results due to the inter …

Tumor immune microenvironment is a very complex system that is influenced by a wide
range of factors; in this microenvironment, various immune cells, stromal cells, and cytokines …